ORTEXORTEX News
Tracking DIS? Get live short interest, options flow, and signals on ORTEX.Sign up free →
DI
Trader NoteDIS

Disney Stock Report: Week of April 20, 2026

By ORTEX News · Edited by , Editor, ORTEX News2 min readdata as of 22 Apr 2026, 21:43

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Executive Summary

DIS closed at $104.29 on April 21, down 1.89% on the day but up 1.66% for the week. The stock has gained 4.80% over the past month. Market cap stands at $184.8 billion.

Key Metrics

MetricValueChange
Price$104.29-1.89% (1d), +1.66% (1w), +4.80% (1m)
Market Cap$184.8B—
Short Interest % FF1.15%-9.25% (1w), -6.57% (1m)
Days to Cover1.65Down from 1.87
Cost to Borrow0.37%+91.9% (1w), +92.9% (1m)
Utilization1.04%Below 52w high of 1.71%
Availability % of SI9,604%Very high

Short Interest Analysis

Disney's short interest continues its downward trend. Short shares fell to 20.6 million as of March 31, down 9.25% week-over-week and 6.57% month-over-month. At just 1.15% of free float, DIS carries minimal short pressure compared to its entertainment sector peers.

Days to cover dropped to 1.65 from 1.87 two weeks prior. This reflects both declining short interest and improved liquidity. The extremely high availability (9,604% of SI) indicates abundant shares to borrow for short sellers, though few appear interested.

Cost to borrow nearly doubled over the past week to 0.37%, though it remains very low in absolute terms. This uptick suggests modestly increasing friction for shorts despite overall declining positions.

Options Sentiment

The put/call ratio (PCR) sits at 0.75, below the 20-day average of 0.79. The PCR z-score of -1.67 indicates stronger-than-normal bullish sentiment. Over the past month, the PCR has declined steadily from 0.91 to current levels, signaling growing optimism among options traders.

The PCR remains well above the 52-week low of 0.66 but far below the March high of 0.97, suggesting moderate bullish positioning rather than extreme optimism.

ORTEX Stock Scores

Disney's ORTEX Total Stock Score stands at 77.49 out of 100 as of April 22, indicating above-average overall quality:

  • Quality Score: 69.06 — Solid fundamentals and balance sheet strength
  • Momentum Score: 63.59 — Improving price momentum and technical indicators
  • Growth Score: 62.54 — Moderate growth outlook
  • Value Score: 60.91 — Fair valuation relative to fundamentals

The momentum score has climbed from 54.8 on March 31 to 63.6 currently, reflecting the stock's recent uptrend. Quality scores have held steady in the high 60s to low 70s throughout the period.

Technical Indicators

The RSI-14 reading of 60.58 suggests DIS is in neutral-to-bullish territory without being overbought. The stock's year-to-date performance shows an 8.33% decline, underperforming the broader market despite recent gains.

Upcoming Catalyst

Disney's next earnings call is scheduled for May 6, 2026 at 12:30 PM UTC. This Q2 2026 report will be closely watched for streaming subscriber trends, theme park attendance, and box office performance.

Analyst Outlook

Analysts project an average return potential of 22.98% from current levels, suggesting consensus price targets well above $100. The forward dividend yield of 1.47% provides modest income while investors await capital appreciation.


This data is provided for informational purposes only and does not constitute financial advice. Market data as of April 21-22, 2026.

Stocks in this article

See the live data behind this article on ORTEX.

Open DIS on ORTEX →

How this article was generated

Generated
22 Apr 2026, 21:43
Data as of
22 Apr 2026, 21:43
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioning

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.